EUVIMEDObjevte EUVIMED
Video/AudioKohortenstudie

Clinical Outcomes of Anti-VEGF Monotherapy Versus Combination Therapy in Diabetic Macular Edema: A Retrospective Cohort Study

Lei Xi, Wentao Li, Feng Zhao

Journal of Visualized Experiments · 2026

DOI: 10.3791/70675 ↗

At a glance

Video/Audio in Journal of Visualized Experiments, 2026. Written by Lei Xi and 2 co-authors. Institution: Department of Ophthalmology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University. Major MEDLINE topics: Macular Edema, Vascular Endothelial Growth Factor A, Diabetic Retinopathy, Angiogenesis Inhibitors. 38 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Diabetic macular edema (DME) is a leading cause of blindness involving vascular endothelial growth factor (VEGF) leakage and inflammation. This retrospective, single-center cohort study evaluated the efficacy and safety of intravitreal anti-VEGF monotherapy versus combination therapy with anti-VEGF plus dexamethasone implant in DME. A total of 200 patients (one eye per patient) treated between January 2021 and December 2024 were included, with 100 receiving anti-VEGF monotherapy and 100 receiving combination therapy. Best-corrected visual acuity (BCVA), central macular thickness (CMT), adverse events, and quality of life (NEI-VFQ-25) were assessed at baseline and at 1, 3, and 6 months. At 1 and 3 months, the combination therapy group showed faster improvement in BCVA (0.53±0.14 vs. 0.61±0.14 at 1 month; 0.46±0.13 vs. 0.53±0.12 at 3 months) and CMT (342±52 µm vs. 380±55 µm at 1 month; 315±48 µm vs. 345±50 µm at 3 months) compared with the monotherapy group (all P < 0.05), along with a higher rapid response rate (68.0% vs. 42.0%, P < 0.001). However, these differences were no longer significant at 6 months. The combination therapy group had higher rates of elevated intraocular pressure (18% vs. 6%, P < 0.05) and cataract progression (12% vs. 3%, P < 0.05). In conclusion, combination therapy was associated with faster early improvement in visual acuity and macular edema resolution within the first 3 months, but this early advantage was not sustained at 6 months and was accompanied by increased risks of elevated intraocular pressure and cataract progression.

Subjects

MeSH terms (MEDLINE)

Macular EdemaVascular Endothelial Growth Factor ADiabetic RetinopathyAngiogenesis InhibitorsHumansRetrospective StudiesDexamethasoneDrug Therapy, CombinationFemaleMaleMiddle AgedVisual AcuityBevacizumabTreatment OutcomeIntravitreal InjectionsRanibizumabAgedCohort Studies

Substances

DexamethasoneVascular Endothelial Growth Factor AAngiogenesis InhibitorsBevacizumabRanibizumab

Authors and institutions

  • Department of Ophthalmology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University.
  • Department of Ophthalmology, Huizhou Third People's Hospital, Guangzhou Medical University.
  • Zhongshan Ophthalmic Center, Sun Yat-sen University, (State Key Laboratory of Ophthalmology), (Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science); zhaofeng1022@hotmail.com.

Cite

APA

Xi, L., Li, W., & Zhao, F. (2026). Clinical Outcomes of Anti-VEGF Monotherapy Versus Combination Therapy in Diabetic Macular Edema: A Retrospective Cohort Study. Journal of Visualized Experiments. https://doi.org/10.3791/70675

Vancouver

Xi L, Li W, Zhao F. Clinical Outcomes of Anti-VEGF Monotherapy Versus Combination Therapy in Diabetic Macular Edema: A Retrospective Cohort Study. Journal of Visualized Experiments. 2026. doi:10.3791/70675

BibTeX
@article{Xi2026,
  author = {Xi, Lei and Li, Wentao and Zhao, Feng},
  title = {Clinical Outcomes of Anti-VEGF Monotherapy Versus Combination Therapy in Diabetic Macular Edema: A Retrospective Cohort Study},
  journal = {Journal of Visualized Experiments},
  year = {2026},
  doi = {10.3791/70675}
}
Start for free →